.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing non-muscle invasive bladder cancer often relies on intravesical bladder cancer therapy. However, current drug delivery methods frequently struggle with poor target specificity and short retention times. To address these challenges, researchers have developed a bioinspired nanoplatform that mimics the multivalent binding of immunoglobulin M (IgM). This innovative system, known as TYS-HSA, significantly enhances the efficacy of albumin-based therapeutics.
The TYS-HSA system utilizes a tandem Y-shaped Sgc8 aptamer-albumin delivery structure. Researchers grafted hydrophilic aptamers onto the hydrophobic side chains of a specific polymer to create multivalent units. These units then self-assemble with human serum albumin (HSA) to form an IgM-like ligand corona. Consequently, each nanoparticle carries approximately 240 aptamers. This high valency ensures stable and high-affinity recognition of cancer cells.
Notably, the platform maintains a strong loading capacity for hydrophobic drugs like paclitaxel. In orthotopic bladder cancer models, the TYS-HSA platform demonstrated superior performance compared to lower-valency conjugates. It achieved prolonged cellular retention and potent antitumor effects after just a single administration. Furthermore, the platform shows broad drug compatibility and excellent physiological stability. This strategy offers a promising path for designing the next generation of targeted albumin nanomedicines.
The design mimics the multivalent structure of IgM, which allows for cooperative binding. This creates a stronger and more stable connection to cancer cells. This mechanism effectively prevents the drug from being washed away during urine voiding.
The TYS-HSA platform is specifically designed for hydrophobic drugs. In laboratory tests, it successfully carried and delivered paclitaxel while maintaining high target specificity and stable drug loading.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Yao W et al. Bioinspired IgM-Mimetic Polyvalent Aptamer-Albumin Nanoplatform for Targeted Intravesical Therapy of Bladder Cancer. Small. 2026 Mar 19. doi: 10.1002/smll.202514393. PMID: 41853972.
Ruan S et al. Albumin-based nanoplatform for targeted cancer therapy. Frontiers in Pharmacology. 2018. doi: 10.3389/fphar.2018.01321.
Chevli L et al. Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning. PMC. 2022. PMCID: PMC9634789.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers develop an IgM-mimetic aptamer-albumin nanoplatform (TYS-HSA) to improve drug retention and efficacy in intravesical bladder cancer therapy....
5 months ago
A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
